Strain Profile
Save
Bifidobacterium breve A1
◔
Human-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Bifidobacterium breve A1 has been studied in the context of cognitive health, including randomized, double-blind, placebo-controlled trials in older adults with mild cognitive impairment examining memory-related outcomes. Animal studies have examined neuroinflammation, amyloid-beta accumulation, and neuroprotective signaling pathways in models of Alzheimer's and Parkinson's disease. This strain represents one of the more clinically studied examples within gut-brain axis research, though the human trials are relatively small and short-term. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 14 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 1 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
16 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2026
REVIEW
2024
ANIMAL
2023
ANIMAL
2021
RCT
2021
ANIMAL
2021
RCT
2021
ANIMAL
2020
RCT
2019
RCT
2019
OBSERVATIONAL
2018
ANIMAL
2017
ANIMAL
2026
REVIEW
2020
REVIEW
2025
REVIEW
2024
REVIEW
Browse all 16 papers →
TARGETING GUT-BRAIN AXIS: POTENSI BIFIDOBACTERIUM BREVE A1 SEBAGAI TERAPI NEUROPROTEKTIF BARU PADA PENYAKIT ALZHEIMER
· Ibnu Sina Jurnal Kedokteran dan Kesehatan-Fakultas Kedokteran Universitas Islam Sumatera Utara
Oral Administration of Probiotic Bifidobacterium breve Ameliorates Tonic–Clonic Seizure in a Pentylenetetrazole-Induced Kindling Mouse Model via Integrin-Linked Kinase Signaling
· International Journal of Molecular Sciences
Effect of oral administration of probiotic Bifidobacterium breve on epileptic seizures in a mouse model of kindling induced by pentylenetetrazole
· Proceedings for Annual Meeting of The Japanese Pharmacological Society
Anti‐inflammation as one of the mechanisms in the improvement of cognitive function by probiotic Bifidobacterium breve strain
· Alzheimer s & Dementia
Oral Administration of Probiotic Bifidobacterium breve Improves Facilitation of Hippocampal Memory Extinction via Restoration of Aberrant Higher Induction of Neuropsin in an MPTP-Induced Mouse Model of Parkinson’s Disease
· Biomedicines
Association of Plasma Hemoglobin A1c with Improvement of Cognitive Functions by Probiotic Bifidobacterium breve Supplementation in Healthy Adults with Mild Cognitive Impairment
· Journal of Alzheimer s Disease
Probiotic Bifidobacterium breve decreases Aβ production via the upregulation of ADAM10 level and attenuates microglia activation in an APP knock‐in mouse model of Alzheimer’s disease
· Alzheimer s & Dementia
Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial
· Journal of Alzheimer s Disease
Effects of Bifidobacterium breve A1 on the cognitive function of older adults with memory complaints: a randomised, double-blind, placebo-controlled trial
· Beneficial Microbes
Bifidobacterium Breve A1 Supplementation Improved Cognitive Decline in Older Adults with Mild Cognitive Impairment: An Open-Label, Single-Arm Study
· The Journal of Prevention of Alzheimer s Disease
P1‐089: ADMINISTRATION OF BIFIDOBACTERIUM BREV E STRAIN A1 PREVENTS COGNITIVE IMPAIRMENT IN AN ALZHEIMER'S DISEASE MODEL MOUSE
· Alzheimer s & Dementia
Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease
· Scientific Reports
Probiotic Interventions and Cognitive Performance: Insights from Recent Clinical Trials
· Current Pharmaceutical Design
T174. ANTIPSYCHOTICS AND THE MICROBIOME
· Schizophrenia Bulletin
Microbiota and Alzheimer's disease: Toward new clinical approaches
· Medicinski podmladak
Extending Healthy Life Expectancy Through the Study of Brain-Gut-Microbiota Axis
· KAGAKU TO SEIBUTSU
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
Source →Probiotic Bifidobacterium breve decreases Aβ production via the upregulation of ADAM10 level and attenuates microglia activation in an APP knock‐in mouse model of Alzheimer’s disease· Alzheimer s & Dementia · 2021
-
[2]
PMID 32623402 →Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial· Journal of Alzheimer s Disease · 2020
-
[3]
PMID 30569089 →Bifidobacterium Breve A1 Supplementation Improved Cognitive Decline in Older Adults with Mild Cognitive Impairment: An Open-Label, Single-Arm Study· The Journal of Prevention of Alzheimer s Disease · 2019
-
[4]
PMID 29044140 →Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease· Scientific Reports · 2017